Abstract:
This invention relates to deployable hemostatic materials comprising chitosan fibers. The hemostatic materials are suitable for use in sealing or controlling active bleeding from artery and vein lacerations and punctures, and for controlling oozing from tissue.
Abstract:
A substance is disclosed for preventing, delaying the onset of or treating one or more than one autoimmune disease, the substance comprising a combination of a polynucleotide construct comprising a polynucleotide sequence encoding ”BCL-2 and encoding one or more than one autoantigen for the autoimmune disease. A use is also disclosed of a polynucleotide construct comprising a combination of a polynucleotide construct comprising a polynucleotide sequence encoding ”BCL-2 and encoding one or more than one autoantigen for the autoimmune disease, for the manufacture of a medicament for preventing, delaying the onset of or treating one or more than one autoimmune disease.
Abstract:
A substance is disclosed for preventing, delaying the onset of or treating one or more than one autoimmune disease, the substance comprising a combination of a polynucleotide construct comprising a polynucleotide sequence encoding ”BCL-2 and encoding one or more than one autoantigen for the autoimmune disease. A use is also disclosed of a polynucleotide construct comprising a combination of a polynucleotide construct comprising a polynucleotide sequence encoding ”BCL-2 and encoding one or more than one autoantigen for the autoimmune disease, for the manufacture of a medicament for preventing, delaying the onset of or treating one or more than one autoimmune disease.
Abstract:
An apparatus (430) for closing a vascular wound includes an apparatus that can be threaded over a guidewire(458) into place at or adjacent the wound. The apparatus includes a chamber(520) that encloses a hemostatic material (270) therein. When the apparatus is positioned adjacent the wound as desired, the hemostatic material is deployed from the chamber. Blood contacts the hemostatic material, and blood clotting preferably is facilitated by a hemostatic agent within the material. Thus, the vascular puncture wound is sealed by blood clot formation.
Abstract:
Use of an enantiomerically stable R-NSAID or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or delaying the onset of symptoms of Alzheimer's Disease, said medicament being substantially free of the S-enantiomer of said R-NSAID.
Abstract:
A method and apparatus for closing a vascular wound includes a guidewire and/or other surgical implement extending from the wound. A hemostatic material is advanced over the surgical implement and into contact with an area of the blood vessel surrounding the wound. The surgical implement is removed. Blood soaks the hemostatic material, and blood clotting is facilitated by the hemostatic agent within the material. A sealing layer of adhesive can be applied to the hemostatic material, confining the blood flow to the material. Thus, the vascular puncture wound is sealed by natural blood clot formation.
Abstract:
A method of seismic retrofitting a concrete structure (22) includes removing material from a portion of the concrete structure with a laser (30) and positioning a stabilizing structure (56) to provide support for the structure.
Abstract:
A fusion gene is provided comprising the cDNA of Renilla luciferase and the cDNA of the 'humanized' Aequorea green fluorescent protein. The fusion gene was used to produce a novel protein, the 'Renilla-GFP fusion protein', which displayed both the luciferase activity of Renilla luciferase, and the green fluorescence of GFP. The Renilla-GFP fusion gene is useful as a double marker for monitoring gene expression quantitatively in UV light and by enzyme activity.
Abstract:
A nanodosimeter device (15) for detecting positive ions induced in a sensitive gas volume by a radiation field of primary particle, comprising an ionization chamber (10) for holding the sensitive gas volume to be irradiated by the radiation field of primary particles; an ion counter system connected to the ionization chamber (10) for detecting the positive ions which pass through the aperture opening and arrive at the ion counter (12) at an arrival time; a particle tracking system for position-sensitive detection of the primary particles passing through the sensitive gas volume; and a data acquisition system capable of coordinating the readout of all data signals and of performing data analysis correlating the arrival time of the positive ions detected by the ion counter system relative to the position sensitive data of primary particles detected by the particle tracking system. The invention further includes the use of the nanodosimeter for method of calibrating radiation exposure with damage to a nucleic acid within a sample. A volume of tissue-equivalent gas is radiated with a radiation field to induce positive ions. The resulting positive ions are measured and compared with a determination of presence or extent of damage resulting from irradiating a nucleic acid sample with an equivalent dose of radiation.
Abstract:
A system (100) for delivering two types of particles to a target within the body of a patient (142). A proton beam therapy system (100) produces a beam of protons (151) that is directed from a nozzle (150) towards a target isocenter (144) located within the body of a patient (142). The beam of protons (151) can pass directly to the patient or pass through a neutron source (104) comprised of a plate of neutron-rich material (154). Collisions between some of the protons and neutrons cause neutrons to be emitted from the material thereby generating a multiple particle beam (170) comprised of both protons and neutrons. Preferably, the neutrons comprise only a small percent of the total particles in the beam. In the preferred embodiment, the neutron source (104) is comprised of a plate of Beryllium (154) that is interposed between the nozzle (150) and the patient (142).